Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT
NMPA GRANTED MARKETING APPROVAL FOR ZYLOX OCTOPLUS® RETRIEVABLE INFERIOR VENA CAVA FILTER

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**", "**we**" or "**our**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that, on December 14, 2022, our Retrievable Inferior Vena Cava Filter–ZYLOX Octoplus™, independently developed by the Company, was granted marketing approval by the National Medical Products Administration (the "**NMPA**") of the People's Republic of China ("**China**") for the prevention of pulmonary embolism (PE) mainly caused by deep vein thrombosis (DVT) in the peripheral vasculature as the Company had expected. As of the date of this announcement, the Company has obtained NMPA approvals for a total of 19 products in China.

For the NMPA approval, we have completed a multi-center, randomized and positive control clinical trial in China to evaluate the safety and efficacy of the product. The trial was conducted and completed in nine well-known peripheral vascular intervention centers in China with Beijing Jishuitan Hospital as the lead principal investigation institution. Overall, the trial results fully demonstrated the safety and efficacy of ZYLOX Octoplus™.

The product features innovative design, instant and excellent adherent performance and self-balancing ability, which enables a more accurate release of the product and more efficient thrombus interception over the the long-term. Meanwhile ZYLOX Octoplus™ is expected to reduce the risk of PE in patients, providing a longer treatment window for thrombolytic therapy and improving the success rate of DVT treatment.

Among peripheral venous diseases, DVT has significant market potential. As disclosed in the Company's prospectus dated June 22, 2021, the number of DVT incidence in China is estimated to increase to 3.3 million in 2030 from 1.5 million in 2019 at a compound annual growth rate ("**CAGR**") of 7.3%. Interventional procedures, including inferior vena cava filter (IVCF) therapy, have become the first choice for DVT of lower extremity in China. According to the same source, the number of IVCF interventional procedures in China is estimated to increase from 85.7 thousand in 2019 to 673.7 thousand in 2030 at a CAGR of 20.6%.

This latest product approval again demonstrates the Company's research and development (R&D) and innovation capabilities in the treatment of peripheral venous diseases. The Company will continue to advance its product portfolio to address the unmet clinical needs of and provide total solutions for patients in China.

By order of the board of directors
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, December 14, 2022

As of the date of this announcement, the Board of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.